An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: Kinetic binding studies with the ALI/VFL-SI/TT mutant

Neuroscience Letters

Volumn 462, Issue 3, 2009, Pages 207-212

  Zhong, Huailing ^a   Hansen, Kasper B ^b   Boyle, Noel J ^a   Han, Kiho ^a   Muske, Galina ^a   Huang, Xinyan ^a   Egebjerg, Jan ^b   Sánchez, Connie ^a  

^a LUNDBECK RESEARCH USA   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

Allosteric; Association rate; Dissociation rate; Escitalopram; Selective serotonin reuptake inhibitor (SSRI); Serotonin transporter

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; NISOXETINE; PAROXETINE; SEROTONIN TRANSPORTER; SERTRALINE;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING KINETICS; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; HUMAN; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RACEMIC MIXTURE;

ALLOSTERIC SITE; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CITALOPRAM; CRICETINAE; CRICETULUS; DRUG ANTAGONISM; HUMANS; KINETICS; MUTATION; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM;

EID: 67849119253     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.07.030     Document Type: Article

References (30)

1. Andersen J., Taboureau O., Hansen K.B., Olsen L., Egebjerg J., Strømgaard K., and Kristensen A.S. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J. Biol. Chem. 284 (2009) 10276-10284
2. Apparsundaram S., Stockdale D.J., Henningsen R.A., Milla M.E., and Martin R.S. Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism. J. Pharmacol Exp. Ther. 327 (2008) 982-990
3. Blier P., and De Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21 (1999) 91S-98S
4. Carneiro A.M., and Blakely R.D. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J. Biol. Chem. 281 (2006) 24769-24780
5. Changeux J.P., and Edelstein S.J. Allosteric mechanisms of signal transduction. Science 308 (2005) 1424-1428
6. Chanrion B., Mannoury la C.C., Bertaso F., Lerner-Natoli M., Freissmuth M., Millan M.J., Bockaert J., and Marin P. Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity. Proc. Natl. Acad. Sci. U S A 104 (2007) 8119-8124
7. Chen F., Larsen M.B., Neubauer H.A., Sanchez C., Plenge P., and Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J. Neurochem. 92 (2005) 21-28
8. Chen F., Larsen M.B., Sanchez C., and Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol. 15 (2005) 193-198
9. Fabre V., and Hamon M. Mechanisms of action of antidepressants: new data from Escitalopram. Encephale 29 (2003) 259-265
10. Gao Z.G., and Jacobson K.A. Keynote review: allosterism in membrane receptors. Drug Discov. Today 11 (2006) 191-202
11. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci. 28 (2007) 407-415
12. Mansari M.E., Sanchez C., Chouvet G., Renaud B., and Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30 (2005) 1269-1277
13. Mansari M.E., Wiborg O., Mnie-Filali O., Benturquia N., Sanchez C., and Haddjeri N. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int. J. Neuropsychopharmacol. 10 (2007) 31-40
14. Mnie-Filali O., Faure C., Mansari M.E., Lambas-Senas L., Berod A., Zimmer L., Sanchez C., and Haddjeri N. R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport 18 (2007) 1553-1556
15. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M., Lam R.W., Lepine J.P., Moller H.J., Nutt D.J., Rouillon F., Schatzberg A.F., and Thase M.E. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int. Clin. Psychopharmacol. 22 (2007) 323-329
16. Neubauer H.A., Hansen C.G., and Wiborg O. Dissection of an allosteric mechanism on the serotonin transporter: a cross-species study. Mol. Pharmacol. 69 (2006) 1242-1250
17. Owens M.J. New pharmacological tools in evaluation of antidepressant molecules. Eur. Neuropsychopharmacol. 17 (2007) S610
18. Plenge P., Gether U., and Rasmussen S.G. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. Eur. J. Pharmacol. 567 (2007) 1-9
19. 3H]paroxetine binding to platelet and neuronal membranes. Eur. J. Pharmacol. 119 (1985) 1-8
20. Plenge P., and Mellerup E.T. An affinity-modulating site on neuronal monoamine transport proteins. Pharmacol. Toxicol. 80 (1997) 197-201
21. Quick M.W. Regulating the conducting states of a mammalian serotonin transporter. Neuron 40 (2003) 537-549
22. Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin. Pharmacol. Toxicol. 99 (2006) 91-95
23. Sanchez C., Bergqvist P.B., Brennum L.T., Gupta S., Hogg S., Larsen A., and Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacol. (Berl.) 167 (2003) 353-362
24. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., and Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacol. (Berl.). 174 (2004) 163-176
25. Singh S.K., Yamashita A., and Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448 (2007) 952-956
26. Torres G.E., Yao W.D., Mohn A.R., Quan H., Kim K.M., Levey A.I., Staudinger J., and Caron M.G. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30 (2001) 121-134
27. Wade A., Gembert K., and Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin. 23 (2007) 1605-1614
28. Zhang Y.W., and Rudnick G. The cytoplasmic substrate permeation pathway of serotonin transporter. J. Biol Chem. 281 (2006) 36213-36220
29. Zhou Z., Zhen J., Karpowich N.K., Goetz R.M., Law C.J., Reith M.E., and Wang D.N. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317 (2007) 1390-1393
30. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E., and Wang D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol. 16 (2009) 652-657